Moderna files for emergency use authorization for its COVID-19 vaccine for ages 12 to 17
Video above: Moderna working to have COVID-19 vaccines for children as young as 5 by early fall
Moderna filed for emergency use authorization with the Food and Drug Administration for its COVID-19 vaccine for people ages 12 to 17, according to a news release from the company.
Moderna's vaccine is currently authorized for people 18 and older.
Last month, from a Phase 2/3 trial of 3,732 children aged 12 to 17 in the United States; blood tests showed that the vaccine produced an immune response that was equivalent to earlier findings in adults. In that trial, initial observations found that none of the children who received the vaccine got sick with COVID-19 starting 14 days after their second dose. Four of the children who received the placebo tested positive for COVID-19.
The company has already filed for younger-age vaccine authorization with regulators in Canada and Europe.
Pfizer received authorization for people as young as 12 to use its coronavirus vaccine on May 10.
The other COVID-19 vaccine available for use in the United States, made by Johnson & Johnson and also known as the Jansen vaccine, is currently authorized for for people 18 and older.